Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.59 |
| ▸ | RXRB | P28702 | 3/20 | 0.56 |
| ▸ | RXRG | P48443 | 3/20 | 0.56 |
| ▸ | RARA | P10276 | 2/20 | 0.56 |
| ▸ | RARB | P10826 | 2/20 | 0.56 |
| ▸ | RARG | P13631 | 2/20 | 0.56 |
| ▸ | HNF4A | P41235 | 6/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861140 | 0.88 | RXRA (0.63) | RXRARXRBRXRGRARARARB | |
| SCHEMBL727284 | 0.87 | RXRA (0.60) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6834543 | 0.85 | RXRA (0.58) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6838361 | 0.84 | RXRA (0.49) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6914132 | 0.81 | RXRA (0.54) | RXRARXRBRXRGRARARARB | |
| SCHEMBL5860148 | 0.80 | RXRA (0.55) | RXRARXRBRXRGRARARARB | |
| SCHEMBL5860153 | 0.80 | RXRA (0.55) | RXRARXRBRXRGRARARARB | |
| SCHEMBL727908 | 0.79 | RXRA (0.62) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6916140 | 0.78 | RXRA (0.61) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6916820 | 0.78 | RXRA (0.58) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019034-B2 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | ALLERGAN, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040147611-A1 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | ALLERGAN, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147611-A1 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RXRG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.